Patents Assigned to Intra-Cellular Therapies, Inc.
-
Patent number: 11957791Abstract: The present disclosure relates to solid oral dosage forms comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.Type: GrantFiled: August 30, 2019Date of Patent: April 16, 2024Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Robert Davis, William Paul Findlay
-
Patent number: 11958852Abstract: The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia.Type: GrantFiled: August 18, 2021Date of Patent: April 16, 2024Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon Mates, Robert Davis, Kimberly Vanover, Lawrence Wennogle
-
Publication number: 20240115565Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-l-one, together with methods of making and using them, and pharmaceutical compositions comprising them.Type: ApplicationFiled: October 17, 2023Publication date: April 11, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventor: Peng LI
-
Publication number: 20240091224Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.Type: ApplicationFiled: November 8, 2023Publication date: March 21, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng LI, Robert DAVIS
-
Publication number: 20240066030Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.Type: ApplicationFiled: October 25, 2023Publication date: February 29, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon MATES, Robert DAVIS, Kimberly VANOVER
-
Publication number: 20240041871Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.Type: ApplicationFiled: October 4, 2023Publication date: February 8, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
-
Publication number: 20240033262Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.Type: ApplicationFiled: September 29, 2023Publication date: February 1, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng LI, Robert DAVIS
-
Publication number: 20240024334Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.Type: ApplicationFiled: October 4, 2023Publication date: January 25, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Kimberly VANOVER, Peng LI, Sharon MATES, Robert DAVIS, Lawrence P. WENNOGLE
-
Publication number: 20240016802Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.Type: ApplicationFiled: September 27, 2023Publication date: January 18, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng LI, Wei YAO, Robert DAVIS
-
Patent number: 11872223Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.Type: GrantFiled: March 16, 2022Date of Patent: January 16, 2024Assignee: INTRA-CELLULAR THERAPIES, INC.Inventor: Peng Li
-
Publication number: 20240000781Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.Type: ApplicationFiled: September 15, 2023Publication date: January 4, 2024Applicant: INTRA-CELLULAR THERAPIES, INC.Inventor: Peng Li
-
Patent number: 11844757Abstract: The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.Type: GrantFiled: September 9, 2020Date of Patent: December 19, 2023Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Wei Yao, Peng Li, Robert Davis, Sharon Mates, Kimberly Vanover, Gretchen Snyder
-
Patent number: 11839614Abstract: The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and/or lusitropic dysfunction, and/or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.Type: GrantFiled: January 31, 2019Date of Patent: December 12, 2023Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: David Kass, Toru Hashimoto, Lawrence Wennogle, Joseph Hendrick, Robert Davis
-
Patent number: 11826367Abstract: The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.Type: GrantFiled: April 13, 2022Date of Patent: November 28, 2023Assignee: INTRA-CELLULAR THERAPIES, INC.Inventor: Peng Li
-
Publication number: 20230355616Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson’s disease or any combinations.Type: ApplicationFiled: February 15, 2023Publication date: November 9, 2023Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Sharon MATES, Allen FIENBERG, Lawrence P. WENNOGLE
-
Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate
Patent number: 11806348Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.Type: GrantFiled: January 24, 2022Date of Patent: November 7, 2023Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Robert Davis -
Patent number: 11806347Abstract: The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.Type: GrantFiled: June 3, 2021Date of Patent: November 7, 2023Assignee: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng Li, Wei Yao, Robert Davis
-
Publication number: 20230346787Abstract: The invention relates to particular substituted deuterated heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.Type: ApplicationFiled: June 22, 2023Publication date: November 2, 2023Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Wei YAO, Peng LI
-
Publication number: 20230339951Abstract: The invention relates to pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) pathway and/or the dopamine D2 receptor pathway, and methods of treating conditions of the central nervous system therewith.Type: ApplicationFiled: June 1, 2023Publication date: October 26, 2023Applicant: INTRA-CELLULAR THERAPIES, INC.Inventors: Peng LI, Qiang ZHANG, Robert DAVIS, Lawrence P. WENNOGLE
-
Publication number: 20230312573Abstract: The disclosure provides salts and crystal forms of a substituted heterocycle fused gamma-carboline, the manufacture thereof, pharmaceutical compositions thereof, and use thereof, e.g., in the treatment of diseases or abnormal conditions involving or mediated by the 5-HT2A receptor, serotonin transporter (SERT), and/or dopamine D1/D2 receptor signaling pathways.Type: ApplicationFiled: September 3, 2021Publication date: October 5, 2023Applicant: INTRA-CELLULAR THERAPIES, INC.Inventor: Peng LI